Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP1 | P11387 | 4/20 | 0.53 |
| ▸ | CYCS | P99999 | 4/20 | 0.52 |
| ▸ | STAT3 | P40763 | 1/20 | 0.44 |
| ▸ | STAT1 | P42224 | 1/20 | 0.44 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.43 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.42 |
| ▸ | TERT | O14746 | 4/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8948212 | 0.90 | TOP1 (0.47) | TOP1CYCSSTAT3STAT1ABCG2 | |
| SCHEMBL10332877 | 0.90 | TOP1 (0.47) | TOP1CYCSSTAT3STAT1ABCG2 | |
| SCHEMBL9432570 | 0.90 | TOP1 (0.47) | TOP1CYCSSTAT3STAT1ABCG2 | |
| SCHEMBL7112999 | 0.90 | TOP1 (0.47) | TOP1CYCSSTAT3STAT1ABCG2 | |
| Hydrochloric Acid SCHEMBL5069023 | 0.89 | TOP1 (0.46) | TOP1CYCSSTAT3STAT1ABCG2 | |
| SCHEMBL2862351 | 0.88 | TOP1 (0.42) | TOP1CYCSSTAT3STAT1ABCG2 | |
| SCHEMBL1538004 | 0.83 | TOP1 (0.56) | TOP1CYCSSTAT3STAT1ABCG2 | |
| SCHEMBL10526144 | 0.82 | TOP1 (0.44) | TOP1CYCSSTAT3STAT1ABCG2 | |
| SCHEMBL9582759 | 0.82 | TOP1 (0.52) | TOP1CYCSSTAT3STAT1ABCG2 | |
| SCHEMBL9582775 | 0.82 | TOP1 (0.54) | TOP1CYCSSTAT3STAT1ABCG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230218663-A1 | COMPOSITIONS AND METHODS FOR TREATING A SARS-COV-2 INFECTION | THE UNIVERSITY OF HONG KONG (CN) | 2023-07-13 | — | — | US | claimed |
| EP-1144345-B1 | METHOD FOR THE COMBINATORIAL SEARCH FOR REACTIONS FOR PRODUCING USEFUL PRODUCTS | MORPHOCHEM AG (DE) | 2003-10-22 | — | — | EP | claimed |
| US-5367070-A | Heat treatment or pyrolysis in the absence of air for clevage | DREXEL UNIVERSITY (US) | 1994-11-22 | — | — | US | claimed |
| EP-0308101-B1 | PREPARATION OF TERTIARY BUTYL ALCOHOL | TEXACO DEVELOPMENT CORPORATION (US) | 1992-07-22 | — | — | EP | claimed |
| EP-0308101-A1 | Preparation of tertiary butyl alcohol | TEXACO DEVELOPMENT CORPORATION (US) | 1989-03-22 | — | — | EP | claimed |
| JP-3030838-A | — | — | None | — | — | JP | disclosed |
| US-20230218663-A1 | COMPOSITIONS AND METHODS FOR TREATING A SARS-COV-2 INFECTION | THE UNIVERSITY OF HONG KONG (CN) | 2023-07-13 | — | — | US | disclosed |
| US-20230218663-A1 | COMPOSITIONS AND METHODS FOR TREATING A SARS-COV-2 INFECTION | THE UNIVERSITY OF HONG KONG (CN) | 2023-07-13 | — | — | US | disclosed |
| CN-115697354-A | Compositions and methods for treating SARS-COV-2 infection | 香港大学 | 2023-02-03 | — | — | CN | disclosed |
| WO-2021244481-A1 | COMPOSITIONS AND METHODS FOR TREATING A SARS-COV-2 INFECTION | THE UNIVERSITY OF HONG KONG (CN) | 2021-12-09 | — | — | WO | disclosed |
| CN-101172973-A | A process for the preparation of pyridine-methylsulfinyl compounds | DIPHARMA FRANCIS SRL (IT) | 2008-05-07 | — | — | CN | disclosed |
| EP-0450594-B1 | DNA probe signal amplification | SEGEV DAVID (US) | 1996-12-18 | — | — | EP | disclosed |
| US-5437977-A | DNA probe signal amplification | Segev, David (IL) | 1995-08-01 | — | — | US | disclosed |
| US-5367070-A | Heat treatment or pyrolysis in the absence of air for clevage | DREXEL UNIVERSITY (US) | 1994-11-22 | — | — | US | disclosed |
| EP-0450594-A2 | DNA probe signal amplification | Segev, David (US) | 1991-10-09 | — | — | EP | disclosed |
| JP-H0330838-A | TETRAPHENYLPORPHYRIN DERIVATIVE AND REDUCTION CATALYST USING IT | CENTRAL RES INST OF ELECTRIC POWER IND | 1991-02-08 | — | — | JP | disclosed |
| EP-0070685-B1 | HOMOGENEOUS NUCLEIC ACID HYBRIDIZATION DIAGNOSTICS BY NON-RADIATIVE ENERGY TRANSFER | AMOCO CORPORATION (US) | 1985-10-16 | — | — | EP | disclosed |
| EP-0070686-B1 | NON-RADIATIVE ENERGY TRANSFER IMMUNOCHEMICAL TECHNIQUE | AMOCO CORPORATION (US) | 1985-10-02 | — | — | EP | disclosed |
| EP-0070686-A2 | Non-radiative energy transfer immunochemical technique | AMOCO CORPORATION (US) | 1983-01-26 | — | — | EP | disclosed |
| EP-0070685-A2 | Homogeneous nucleic acid hybridization diagnostics by non-radiative energy transfer | AMOCO CORPORATION (US) | 1983-01-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230218663-A1 | COMPOSITIONS AND METHODS FOR TREATING A SARS-COV-2 INFECTION | TPP2, TTR, TARBP2 | TOP1 2585/4885CYCS 2072/4885STAT3 4261/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.